Physician profile
Ross Michael Brockman
NPI 1568842185
$108,981.19
in general payments reported to CMS, 2019-2025
19 companies · $44K in 2025
The $44K reported for 2025 was more than what 93% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,223 · 2023: $13K · 2024: $49K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Travel and Lodging: $5,183 · Food and Beverage: $3,769 · Education: $92.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,714.00 |
| Travel and Lodging | $5,183.38 |
| Food and Beverage | $3,768.80 |
| Education | $92.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $74,133.41 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $32,743.33 | 2022-2025 | Dupixent |
| Abbvie INC. | $459.63 | 2022-2024 | |
| Incyte Corporation | $334.56 | 2022-2025 | Opzelura, Opzelura |
| Pfizer INC. | $196.15 | 2023-2025 | |
| Janssen Biotech, INC. | $195.99 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $192.36 | 2022-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $139.82 | 2022-2025 | |
| Lilly USA, LLC | $133.71 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $129.22 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $59.17 | 2022-2023 | Adbry |
| Organon LLC | $55.51 | 2025 | Vtama |
| Ucb, INC. | $47.12 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $36.82 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $34.32 | 2024 | Zoryve |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $31.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.38 | 2024 | Sotyktu |
| Bausch & Lomb Americas INC. | $18.82 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $17.26 | 2024 | Hemangeol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Brockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.